Relevance of experimental paradigms of anesthesia induced neurotoxicity in the mouse

Simon C. Johnson, Amanda Pan, Grace X. Sun, Arielle Freed, Julia C. Stokes, Rebecca Bornstein, Michael Witkowski, Li Li, Jeremy M. Ford, Christopher R. A. Howard, Margaret M. Sedensky, Philip G. Morgan

1 Center for Integrative Brain Research, Seattle Children’s Research Institute, Seattle, WA, United States of America, 2 Department of Neurology, University of Washington, Seattle, WA, United States of America, 3 University of Washington School of Dentistry, Seattle, WA, United States of America, 4 Department of Pathology, University of Washington, Seattle, WA, United States of America, 5 Seattle Children’s Imagination Lab, Seattle Children’s Research Institute, Seattle, WA, United States of America, 6 Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, United States of America

* simon.johnson@seattlechildrens.org

Abstract

Routine general anesthesia is considered to be safe in healthy individuals. However, preclinical studies in mice, rats, and monkeys have repeatedly demonstrated that exposure to anesthetic agents during early post-natal periods can lead to acute neurotoxicity. More concerning, later-life defects in cognition, assessed by behavioral assays for learning and memory, have been reported. Although the potential for anesthetics to damage the neonatal brain is well-documented, the clinical significance of the pre-clinical models in which damage is induced remains quite unclear. Here, we systematically evaluate critical physiological parameters in post-natal day 7 neonatal mice exposed to 1.5% isoflurane for 2–4 hours, the most common anesthesia induced neurotoxicity paradigm in this animal model. We find that 2 or more hours of anesthesia exposure results in dramatic respiratory and metabolic changes that may limit interpretation of this paradigm to the clinical situation. Our data indicate that neonatal mouse models of AIN are not necessarily appropriate representations of human exposures.

Introduction

General anesthesia has been a key feature of modern medicine for over 150 years. Although widely used and generally safe in healthy individuals, neurotoxicity related to anesthetic exposure has been reported in multiple animal models and retrospective clinical studies (reviewed in [1–4]). These studies have linked anesthetic exposure during early post-natal periods to acute anesthesia induced neurotoxicity (AIN) and later-life defects in performance in behavioral assays for learning and memory. This data has generated substantial concern regarding the risks associated with anesthesia in human neonatal and pediatric patients [1,5–7].
In humans, studies of the impact of pediatric anesthetic exposure on cognition and behavior have generally been difficult to interpret. Some retrospective studies have reported mild cognitive defects, such as impaired language skills or abstract reasoning, associated with anesthetic exposure during early childhood, while others have shown no such association [8–10]. Various confounding factors have limited the interpretation of these studies, such as differences in compared populations and an inability to separate the impact of anesthesia from the underlying pathology requiring exposure, or the stress of surgery. The General Anesthesia versus Spinal Anesthesia (GAS) and Pediatric Anesthesia & Neuro Development Assessment (PANDA) studies were designed to directly assess the neurodevelopmental impact of anesthesia while eliminating the majority of confounding effects. Reports from both of these prospective trials revealed no evidence of cognitive defects arising from short anesthetic exposures in neonates [6–11]. Similarly, the SmartTots program has recently reported that available evidence suggests brief clinical exposures do not appear to cause overt cognitive defects in humans, while also calling for increased efforts to improve reproducibility in animal studies [7]. These well-controlled, multicenter studies in children provide the best evidence to date that short clinical anesthetic exposures have minimal or no lasting impact on human cognitive development. The clinical literature is reviewed in depth elsewhere (see [1,5,12,13]). The recent review by Davidson and Sun conclude that the clinical concerns, including the FDA warning, continue to be driven primarily by pre-clinical findings [5].

The lack of measurable effects on cognition in recent multicenter human trials is reassuring, but raises important questions regarding the pre-clinical AIN literature. In particular, while the potential for exposure to anesthetic agents to damage the rodent neonatal brain is clear, the significance of pre-clinical models used to induce damage has not been carefully evaluated. With the initial aim of examining intracellular signaling changes in the AIN paradigm, we performed detailed baseline experiments to define the physiological impact of anesthesia in post-natal day 7 (P7) neonatal mice in the experimental conditions most commonly used for mouse AIN studies. Although there has been some effort to examine physiological parameters in neonatal rodents under anesthesia (see Discussion) an extensive assessment of multiple parameters has been lacking. Here, we report striking physiological and metabolic aberrations caused by common anesthesia paradigms in neonatal mice and discuss the implications of these findings as they apply to the pre-clinical AIN literature. These pathologic responses also give new insights into the potential impact of volatile anesthetics in neonates, which may lead to studies in pediatric patients that improve patient care.

**Materials and methods**

**Ethics statement and animals**

All experiments were approved by the Animal Care and Use Committee of Seattle Children’s Research Institute (Seattle, WA). All experiments utilize the C57Bl/6 strain, originally obtained from Jackson laboratories (Bar Harbor, ME). All treatment group assignments were randomized. Animal numbers for each dataset are noted in the associated figure legends. To increase power all baseline blood parameter datasets for P7 neonates (time = 0 for P7 neonatal anesthesia exposures) were pooled and are common between figures where baseline P7 blood data appears.

**Anesthetic exposures and respiratory rates**

We chose anesthetic conditions consistent with published mouse neonatal AIN literature (see Results, Table 1, Fig 1A). Isoflurane (Piramal Critical Care Inc, NDC66794-013-25) was provided at 1.5% using a routinely maintained and tested isoflurane vaporizer (Patterson...
Veterinary) at a flow-rate of 3–4 liters/min through a humidifier in-line. 100% oxygen was used as the carrier gas. The plexiglass exposure chamber and humidifier were pre-warmed to 38˚ C and maintained at this temperature throughout the exposure using a circulating water heating pad (Adroit Medical, HTP-1500), and the temperature of the heating pad was verified using a thermometer. ‘No isoflurane’ controls were treated identically to isoflurane exposed animals, including removal from parents at P7 for 4 hours and maintenance at 38˚ C during

Table 1. Summary of neonatal mouse AIN literature.

| Age   | Background                      | Anesthetic, dose, and time                                                                 | Ref. |
|-------|--------------------------------|------------------------------------------------------------------------------------------|------|
| P6-8  | C57Bl/6                         | 3% isoflurane: 2 hr/day for 3 days                                                         | [37] |
| P6    | C57Bl/6                         | 3% isoflurane: 6 hours                                                                      | [38] |
| P7    | C57Bl/6                         | Isoflurane: 0.75% for 6 hours; Lidocaine: 4 mg/kg subcutaneous; midazolam: 9 mg/kg subcutaneous | [39] |
| P7    | (F) C57Bl/6 x (M) CD-1 F1 hybrid| 1.5% isoflurane: 6 hours                                                                      | [21] |
| P5-7  | C57Bl/6                         | 0.75% isoflurane: 4 hours 0.75% isoflurane plus midazolam: 6 hrs 1.5% isoflurane: 2 hours 2% isoflurane: 1 hour | [40] |
| P14   | C57Bl/6                         | 1.7% isoflurane: 35 min/day for 4 days                                                      | [41] |
| P6-8  | C57Bl/6                         | 3% isoflurane: 2 hours/day for 3 days                                                       | [42] |
| P6    | C57Bl/6                         | 2.2% sevoflurane: 2 hours per day for 3 days                                                 | [43] |
| P6    | C57Bl/6                         | 2% isoflurane: 2hrs/day for 3 days 8% desflurane: 2 hrs/day for 3 days                      | [44] |
| P10   | 129T2/SvEvMex J x C57Bl6/J F1 hybrid | 3% isoflurane: 90 minutes                                                                   | [18] |
| P6    | C57Bl/6                         | 2% sevoflurane: 6 hours                                                                      | [45] |
| P7    | C57Bl/6                         | 1.5% isoflurane 6 hours or 150 mg/kg propofol                                               | [29] |
| P6-8  | C57Bl/6                         | 3% sevoflurane: 2 hours/day for 3 days                                                      | [46] |
| P7    | C57Bl/6                         | 2.9% sevoflurane: 6 hours or 150 mg/kg propofol                                              | [47] |
| P7    | C57Bl/6                         | 3% sevoflurane: 6 hours (with or without 5 mg/kg thiopental or 10 mg/kg propofol)          | [48] |
| P6-8  | C57Bl/6                         | 3% sevoflurane: 2 hours daily for 3 days                                                     | [49] |
| P7    | C57Bl/6                         | 1.5% isoflurane: 6 hours 2.9% sevoflurane: 6 hours 7.4% desflurane: 6 hours                 | [50] |
| P7    | C57Bl/6                         | 1.5% isoflurane: 2 hours                                                                    | [51] |
| P6-8  | C57Bl/6                         | 3% sevoflurane: 2 hours daily for 3 days                                                     | [52] |
| P7    | CD-1                           | 2% isoflurane: 1 hour                                                                      | [53] |
| P7    | CD-1                           | 2% isoflurane: 1 hour                                                                      | [54] |
| P6-7  | C57Bl/6                         | Sevoflurane: 3.5% for 90 min, 3% for 90 min, then 2.5% for the final 3 hours.                | [55] |
| P7-9  | C57Bl/6                         | 1.5% isoflurane: 2 hours/day for 3 days 2.2% sevoflurane, 2 hours/day for 3 days              | [56] |
| P7-8  | CD-1 male x C57Bl/6 F1 hybrid   | 1.5% isoflurane: 6 hours 2.9% sevoflurane: 6 hours 7.4% desflurane: 6 hours                 | [57] |
| P7, P21, or P49 | C57Bl/6                     | 1.5% isoflurane: 6 hours                                                                  | [58] |
| P7    | C57Bl/6                         | 0.75% isoflurane: 6 hours 1.1% sevoflurane: 6 hours                                         | [59] |

https://doi.org/10.1371/journal.pone.0213543.t001

Veterinary) at a flow-rate of 3–4 liters/min through a humidifier in-line. 100% oxygen was used as the carrier gas. The plexiglass exposure chamber and humidifier were pre-warmed to 38˚ C and maintained at this temperature throughout the exposure using a circulating water heating pad (Adroit Medical, HTP-1500), and the temperature of the heating pad was verified using a thermometer. ‘No isoflurane’ controls were treated identically to isoflurane exposed animals, including removal from parents at P7 for 4 hours and maintenance at 38˚ C during
but exposed to room air. 'Baseline control' animals were not handled prior to behavioral testing aside from standard animal care. Respiratory rates were observed through direct visual observation by counting mouse breathing rate over time.

**Euthanasia and mortality during anesthesia**

Animals used for tissue and blood analyses were euthanized at specific time points by decapitation as approved by our institutional IACUC. Mortality during anesthesia exposure was not expected, based on the published AIN literature, but was observed in our study. In these cases, animals stopped breathing during anesthesia, while fully anesthetized and consistent with approved isoflurane overdose euthanasia or stopped breathing at the time when anesthesia exposure ended. In the latter case, pups were decapitated to ensure humane euthanasia as per our IACUC protocol. All animals were closely monitored throughout exposures and recovery to ensure that all animals were humanely euthanized.
Blood values

Longitudinal collection of blood data is physically impossible in P7 neonatal mice due to their extremely small size. Each blood value measurement therefore represents a single animal euthanized at the timepoint designated. Animals were rapidly euthanized by decapitation, and blood was analyzed immediately. Blood glucose was measured using a Prodigy Autocode glucose meter (product #51850–3466188). The ketone β-hydroxybutyrate (β-HB) was assessed using Precision Xtra XEGW044 meter with β-HB assay strips. Lactate was measured using Nova Biomedical assay meter (Product #40828). pH was measured using a pH Testr 10 BNC meter (Oaklon #2706055) with an Orion micro pH electrode (ThermoScientific, product #9810BN).

Glycogen quantification

Glycogen concentration was assessed using a commercially available enzymatic colorometric assay (Sigma, MAK016) according to manufacture specifications. Briefly, flash frozen tissue samples were cryohomogenized into a frozen tissue powder on dry ice. While in a 4˚ walk-in cold room, a portion of the powder was rapidly moved to a microcentrifuge tube on a tared scale, the mass recorded, and the tube was placed on dry ice. This was performed carefully to prevent thawing. Deionized water was added, while on dry ice, to 20 μL water per mg tissue. The samples were boiled together for 10 minutes, with intermittent vortexing, placed quickly onto wet ice, and sonicated until homogenous with no visible pieces. At this point, an aliquot was removed for protein quantification via bicinchoninic acid (BCA) assay (ThermoFisher, #23225, as per manufacturer protocol) and later normalization against tissue protein mass. Samples were centrifuged at 13,000 rpm in a tabletop centrifuge for 10 minutes at 4˚C, and the supernatant was moved into a new tube on ice. Samples derived from liver were then further diluted by 40X to fit in the range of the standard curve, based on empirical testing. A standard curve of glycogen was prepared with the following concentrations: 1 μg/μL, 0.2 μg/μL, 0.1 μg/μL, 0.05 μg/μL, 0.01 μg/μL, 0.005 μg/μL, 0.001 μg/μL, and 0 μg/μL, each in deionized water. In PCR tubes, 4 μL of sample or standard curve were mixed 6uL Glycogen Hydrolysis Buffer. For each sample/standard, two tubes were prepared, one to serve as a “hydrolysis background control”. 1 μL of 1:5 diluted Hydrolysis enzyme mix was added to samples and standards, but not ‘hydrolysis background control samples.’ 1 μL of Hydrolysis buffer was added to “hydrolysis background controls”. Samples were incubated for 30 min at room temperature, then 8.8 μL Glycogen Development Buffer, 0.4 μL Development Enzyme, and 0.4 μL Probe were added to all tubes. Samples were then incubated for 30 min at room temperature. At the end of this incubation, samples were placed on ice and absorbance was immediately analyzed on a Nanodrop 1000 set to 460nm. Concentrations were calculated using the standard curve, with background subtracted using the ‘hydrolysis background control’ reactions, and the final concentration normalized against tissue protein mass.

Tissue collection and processing

Following euthanasia by decapitation mouse brains were rapidly bisected down the midline. One half of each brain was flash frozen in liquid nitrogen and stored at -80 until used for protein extraction. The other half was placed in ice cold 3.8% paraformaldehyde in 1X PBS and fixed for 24 hours. Following fixation, brains were moved to a cryoprotectant solution (30% sucrose, 1% DMSO, 100 μM glycine, 1X PBS, 0.45 μm filtered, pH 7.5), and stored for over 48 hours, until the fixed tissues sank to the bottom. Tissues were then placed in OCT media.
(Tissue-Tek OCT compound, Sakura 0004348–01), frozen in cryoblock holders on dry ice, and stored at -80 until sectioned for staining.

**Protein extraction and Western blotting**

For protein lysates, the flash frozen brain half was cryo-pulverized on dry ice until a fine powder then dissolved in 1X RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease and phosphatase inhibitor cocktail and 5mM EDTA (Thermo Scientific, 78440). This solution was briefly sonicated so fragment genomic DNA then centrifuged at maximum speed on a table-top centrifuge for 10 min at 4°C. The supernatant was moved to a new tube and protein concentration was determined using the BCA assay (Thermo Scientific, 23227).

Protein samples were run on 26 well 4–12% Tris-EDTA NuPage gels with MOPS running buffer (ThermoFisher, NP0001). 20μg protein were loaded in each well in 1X loading dye (5X dye: 250 mM Tris- HCl, 10% SDS, 30% Glycerol, 0.05% bromophenol blue, pH 6.8) with 100 mM DTT in a total volume of 15 μL. Samples were denatured prior to loading by heating to 95 degrees for 2 min. Blots were transferred to nitrocellulose membranes (BioRad, 1704271) using a BioRad Turbo-Transfer system set to 1.3A, 25V, for 5min (BioRad optimized for low molecular weight targets).

Following transfer, blots were briefly stained with Ponceau S (Sigma, P7170) to assess quality and protein loading. Blots were blocked in 10% milk in TBS with 0.5% tween-20 for 1 hour, then primary antibody for 24–72 hours.

Initial attempts to probe entire blot area for cleaved caspase-3 all failed due to binding of antibodies to full-length caspase-3 or non-specific bands. 2 of 4 commercially available antibodies tested failed to detect a band at the correct size for cleaved caspase-3. Of the two antibodies that were successful (Cell Signaling, #9602, also used for immunostaining, and Millipore AB3623, also see text) both required cutting off the upper portion of the western blot membrane above ~25 kDa and incubating the lower portion, containing cleaved caspase-3 band, in primary antibody at a 1:100 dilution. After primary antibody incubation, blots were washed 3 times in 1X TBS, incubated for 1 hour at room temperature in goat anti-rabbit-HRP at a 1:3,000 dilution, washed 3 times, then soaked in chemiluminescent substrate (Supersignal West Pico Plus, ThermoFisher 34580) and exposed to film (CL-XPosure, ThermoScientific 34090). Actin was detected using anti-Actin- horseradish peroxidase (HRP) (Abcam, ab4990) at 1:5,000 on the upper half of the blot. Successful detection of cleaved caspase-3 required extended exposures (film exposed over a weekend). Exposed films were scanned then analyzed using Image J.

**Immunofluorescent staining for cleaved caspase-3**

Frozen brains in cryoblocks were cut at 50 μm thickness using a Leica CM30505 cryostat set at -40 degrees C. Slices were moved to 1X PBS and stored at 4 degrees C until used for staining. Prior to staining, slices were mounted on slides and briefly dried to adhere.

Antibody staining was performed as follows: slides were first treated for 30 min in a gentle antigen retrieval and permeabilization buffer (0.05% Triton X-100, 50 μM digitonin, 10 mM Tris-HCl, 1 mM EDTA, pH 9.0) using the double-boiler method with the lower chamber of water heated to a rapid boil. After 30 minutes the slide chambers were removed from the boiler and slides were allowed to cool to room temperature in the antigen retrieval/permeabilization buffer. To reduce formaldehyde induced background fluorescence, slides were treated with sodium borohydride in ice cold PBS, added at 1 mg/mL immediately before incubation, on ice for 30 min, then moved to 10mM glycine 1XPBS, pH 7.4, for 5 min at room temperature.
Lipid background fluorescence was then blocked by incubating slides in 0.2 um filtered Sudan Black B solution (5 mg/mL in 70% ethanol) for 30 min at room temperature with very gentle motion on a bench-top rotary shaker. Slides were then rinsed twice, 5 min each, in 1X PBS. Excess fluid was wiped from the slide and the tissue was circled using Liquid Blocker PAP pen (Fisher Scientific, NC9827128) to hold staining solutions. Slides were blocked for 15 min at room temperature in 1X PBS with 10% rabbit serum (Gibco, 16120–099—all conjugated primary antibodies were produced in rabbit) then stained overnight at 4˚ C in a mixture of rabbit anti-caspase-3-Alexa647 (Cell Signaling, D3E9, #9602S) at 1:200, rabbit anti-NeuN-Alexa594 (Abcam, #ab207279) at 1:200, and DAPI (Sigma, D9542) at 1 μg/mL. The following day the slides were washed 3X 5 min in 1X PBS then mounted in aqueous mounting media with aqueous anti-fade (90% glycerol, 0.5% n-propyl gallate, 20mM Tris-HCl, pH 8.0), sealed with coverslips, and stored at 4˚ C protected from light until imaging.

Microscopy
All compared images were collected on the same day in the same imaging session using the same imaging parameters.

Slices stained for cleaved caspase-3, NeuN, and DAPI were imaged on a Zeiss LSM 710 confocal microscope. Images of hippocampus were collected using a 10X dry objective at 0.6X optical zoom, resulting in images of 1417 x 1417 microns in physical area. All images of hippocampus were collected at 4096 x 4096 resolution, with 8–16 line averages and a line scan speed of 6–7. The DAPI channel was set to 10-micron optical section thickness, the NeuN-Alexa594 and cleaved caspase-3-Alexa647 were both set to 15-micron thickness. DAPI was excited at 405 nm, with emission light collected using a sliding filter with the range setting at 413–530 nm. NeuN (Alexa594) was excited with a 543 nm laser, emissions collected at 569–665 nm. caspase-3 (Alexa647) was excited at 633 nm and emitted light was collected at 654–698 nm.

Assessment of cognitive function by the Barnes maze test
A Barnes maze was built by our in-house fabrication group, Seattle Children’s Imagination Lab, using publicly available design specifications for commercially available mazes. Our Barnes maze was constructed using a 0.5-inch-thick, 36-inch diameter, high-density polyethylene (HDPE) disk purchased from TAP Plastics, a local fabrication supplier (https://www.tapplastics.com/). A trammel, protractor, and ruler were used to mark 20 equally spaced (18˚) holes, each 16 inches from center of disk, and a drill press and hole saw were used to drill these holes. PVC caps cut to 0.5 inches were adhesively welded into the holes using TAP Poly-Weld Adhesive. The ‘escape’ hole also had a short segment of PVC inserted but this was open at the bottom rather than capped. Razor blades and a palm sander were used to tidy the surface until the entire platform was smooth and flush.

The assembled maze was placed on a platform raising it 4-feet from the ground in a small, well-lit behavior room with no windows and protected from noise. The maze was placed near a corner with unique placards placed at maze-top height on two walls and a bright lamp at about 6-foot height in the corner. The maze was kept in the same orientation at all times. Initially a small, directly attachable ‘exit’ box was used, but in tests we found mice were afraid of the small enclosure and would not return after the first successful trial. We ultimately replaced this with a Kaytee CritterTrail 3’ Elbow Tube which led to a standard mouse housing unit (from our animal facility) which was replaced for each trial. The entire maze surface and elbow tube were thoroughly cleaned with 10% bleach solution [14] after every run and a clean empty cage unit used for every trial to prevent odor mediated cues from disrupting the assessment of learning and memory.
To assess learning and memory we utilized a standard Barnes maze paradigm with a slightly modified trial number to prevent acclimation. Specifically, we tested mice three times on day 1 of week one, twice on days 2 and 3 of week one, then twice on day 1 of week 2, followed by once each on day 1 of week 3 and 6 (see Results). In our assay optimization we found that additional tests, or additional test days, resulting in rapidly worsening maze times, which we interpreted to indicate acclimation to the testing environment and loss of motivation to exit the maze. An assessment of all mice tested using our paradigm shows that both learning (reduction in trial time from trial 0) and memory (maintenance of low trial time) behaviors were successfully observed in this assay (see Results), while only mild acclimation effects were observed and only in males on run 3 of day 1. In addition, to maximize the utility of the assay, we added a test at 6 weeks after the first run to assess long-term memory.

Chemical reagents

Unless stated otherwise, all chemical reagents were purchased from Sigma-Aldrich.

Loss of righting reflex

P7 neonatal mice were placed in an anesthesia chamber as in Fig 1, except that the humidifier was omitted for these brief exposures. Anesthetic flow rate was set to 4 liters per minute for rapid gas replacement in the plexiglass chamber. Animals were exposed incrementally to increasing doses of anesthetic for 10 min each dose, with loss of righting reflex assessed at the end of the 10 minutes. Animals were tested in groups of 4 or less, with a total of 13 individual animals tested with isoflurane and 15 individual animals tested with sevoflurane.

Statistical analyses

All statistical analyses performed using GraphPad Prism version 7.0a. Nonlinear regression and 95% confidence intervals were calculated using a one-phase decay model with least squares regression, no weighting, and no special handling of outliers. All replicate y values were considered individual points, and medium convergence criteria were selected. Asymmetrical 95% confidence intervals are plotted as confidence bands.

All data collected are presented in the manuscript, no data-points were omitted.

All other datasets in Fig 1 were first compared by one-way ANOVA (p-values detailed in Fig legend) followed by post-hoc pairwise two-sided t-test comparisons.

Datasets in Figs 2 and 3 were first compared by one-way ANOVA (p-values detailed in Fig legend) followed by post-hoc pairwise two-sided t-test comparisons.

In Fig 3, a total of 8, 4, 5, 5, and 5 animals were collected for baseline, 1, 2, 3, and 3 hour 1.5% isoflurane exposure cleaved caspase-3 staining. All samples were blinded; all imaging and quantification were performed on blinded specimens. Samples with poor cut quality due to tissue folding or lack of structure of interest (for example, olfactory bulb and cerebellum, which are sometimes lost during slice handling), were not imaged. The number of replicates per region varied based on available quality stained sections, but all quality samples were imaged and analyzed. Data-points in Fig 3 represent biological replicates; n = 6, 2, 5, 5, and 4 for olfactory bulb; n = 6, 2, 2, 3, 3 for cortex; n = 8, 4, 4, 5, 4; and n = 7, 4, 3, 4, 4 for cerebellum.

Data in Fig 4 were analyzed using row by row comparisons via pairwise t-tests. We compared treatment groups to both baseline controls (untreated at P7) and ‘no isoflurane’ controls (mock treatment). No significant differences (by p-value <0.05 cutoff) at any time point in any paradigm, even when no multiple testing correction was applied, thus the least stringent criteria for statistical significance, was used.
Results

Anesthetic approach

We first searched the literature to understand the parameters used in studies of AIN in rodents (see Table 1). We found that although conditions vary widely between individual reports, the majority of studies expose C57Bl/6 mice at around P7 to 2–6 hours of anesthesia. We designed our anesthetic exposure to match the most representative published AIN studies. Accordingly, isoflurane was provided in 100% oxygen at a high flow-rate of 3–4 liters/min with a humidifier in-line, and the exposure chamber, humidified gas, and chamber were pre-warmed to, and maintained at 38˚ C using a circulating water heating pad (Fig 1A, see Methods for additional details). We found 1.5% isoflurane provides effective anesthesia in P7 neonatal mice, as determined by loss of response to tail clamp. 1% isoflurane failed to anesthetize P7 pups, therefore we did not include this sub-anesthetic dose in our studies. Since 1.5% isoflurane is the most commonly used concentration, we exposed P7 pups to 1.5% isoflurane for 2 or 4 hours.

Physiological impact of extended anesthesia exposure in P7 neonatal mice

To query the clinical significance of murine neonatal AIN paradigms we assessed physiological parameters associated with anesthetic exposure.

Exposure to 1.5% isoflurane in P7 neonatal mice causes progressive respiratory depression, leading to severely reduced respiratory rate (RR) at both 2- and 4-hours (Fig 1B and 1C). Mean RR in P7 neonatal mice at rest is ~96 breaths/min; by 2-hours, RR has dropped to ~25.4 breaths/min, further decreasing to 11.5 breaths/min by 4-hours.

We next examined circulating metabolites to assess the impact of extended anesthesia on metabolic status. Baseline glucose in P7 mice is 161 mg/dL; by 2-hours of 1.5% isoflurane glucose has fallen by ~80% to ~35 mg/dL. Glucose fell below the limits of detection (<5 mg/dL) by 4-hours of exposure (Fig 1D). The circulating ketone β-hydroxybutyrate (β-HB) was also
Depleted by 2-hours isoflurane exposure, to approximately 35% of baseline (Fig 1E). Of note, glucose infusion did not attenuate the depletion of β-HB (data not shown).
VAIs, including isoflurane, impair mitochondrial respiration through inhibition of complex I of the mitochondrial electron transport chain [15,16]. This can increase anaerobic metabolism of glucose to lactate. Respiratory depression, as observed here (Fig 1B and 1C), can also increase anaerobic glucose metabolism, increasing lactate. In the setting of increased anaerobic

Fig 4. Cognitive outcomes in anesthesia exposed P7 neonatal mice. (A) Barnes maze setup and Barnes maze testing paradigm (see Methods for details and specifications). (B) Timeline of anesthesia treatment and Barnes maze assessment and anesthesia paradigms explored in this study. (C) Barnes maze paradigm utilized in this study. (D) Composite data from all mice from all treatment cohorts. (E, H) Assessment of female (E) and male (H) animals treated with 2 hours of anesthesia with 1.5% isoflurane mice compared to mock treated controls (see Methods). (F, I) Assessment of female (F) and male (I) animals treated with 4 hours of anesthesia with 1.5% isoflurane or treated 2 hours of 1.5% isoflurane daily for three days compared to mock treated controls (see Methods). (G, J) Assessment of female (G) and male (J) animals given mock treatment compared to animals receiving no handling (aside from routine animal maintenance) prior to behavioral assessment (see Methods). Animal numbers are listed in every panel; in all panels data points represent the mean, error bars represent SEM. Row by row comparisons by pairwise t-tests yielded no significant differences (by p-value < 0.05 cutoff) at any time point in any paradigm, even when no multiple testing correction was applied and thus the least stringent criteria for statistical significance used.

https://doi.org/10.1371/journal.pone.0213543.g004
glucose metabolism, accumulating lactate can lead to metabolic acidosis. Therefore, we measured circulating lactate at 2- and 4-hours of isoflurane exposure. Blood lactate rose by 2-hours to 6.0 mM, from a baseline of 2.8 mM (Fig 1F). Lactate returned to baseline by 4-hours, a reduction presumably the result of depleted substrate (glucose). In agreement with the metabolic and respiratory changes, blood pH progressively dropped; by 4-hours of treatment, average blood pH was 6.98 (Fig 1G). As with the metabolic and respiratory parameters, this shift in blood pH would not be tolerated in a clinical setting.

**Mortality**

All animals treated for 2-hours recovered from the anesthetic exposure. In contrast, while the majority of animals (>90%) treated with 1.5% isoflurane for 4-hours were still alive (judged by visible respiration) at the 4-hour time-point, substantial mortality occurred within a few minutes of removal from isoflurane. In some animals, tremors or brief tonic seizures were observed during the immediate recovery time, presumably resulting from the substantial combined physiological stress of absent blood glucose, depleted ketones, and acidosis. In total, approximately 50% of pups treated for 4-hours and allowed to recover did not survive the recovery period: from 6 independent litters, 17 survived and 18 died (see Fig 1H).

**Recovery time**

Many AIN reports (see references in Table 1) suggest that extended or repeated anesthesia may lead to lasting cognitive defects in mice (although, critically, other reports have found no cognitive effects, see [1] and Discussion). One particularly thorough investigation of AIN in mice reported cognitive defects only at extremely high VA concentrations, after lengthy exposures, or in animals exposed repeatedly- 3 times during the same day [17]. Given the severe metabolic and respiratory impact of anesthesia for even 2-hours, we considered the time necessary for P7 mice to metabolically recover after isoflurane exposure. Blood glucose remains low even at 4 hours after a 2-hour exposure (Fig 2A). Recovery of circulating ketone β-HB takes 4 hours, with β-HB overshooting normal baseline levels at 1, 2, and 3 hours of recovery and taking time to stabilize (Fig 2B). Finally, quantification of liver glycogen demonstrated a depletion of hepatic glycogen stores by 2 hours of exposure which is not replenished until 4 hours of recover (Fig 2C).

**Timeframe of anesthesia induced neurotoxicity**

Increased CNS apoptosis has also been reported in animals anesthetized with VAs for four or more hours. This is typically shown using Western blotting or antibody-based tissue staining for cleaved caspase-3, an effector of apoptosis active only following pro-apoptotic stimuli. To assess induction of apoptosis, we first probed cleaved caspase-3 by western blotting using whole brain lysates (see Methods for tissue collection and processing) from animals exposed to 1.5% isoflurane for 0 or 4 hours, euthanized at the 4 hour timepoint (since the 4 hour samples were taken immediately following anesthetic exposure some of the mice studied would most likely have died during recovery, based on our survival data in Fig 1H). We observed an induction of apoptosis at this 4-hour time-point, as reported by others (Fig 3A). Worth noting, we observed that Western blots required considerable attention to detail, as 2 of the 3 commercially available antibodies only detected proteins whose molecular weights did not match that of cleaved caspase 3 (see Methods).

Given our observations regarding RR, metabolism, blood pH, and survival, we next determined when, in relation to these changes, induction of CNS apoptosis is detectable in P7 mice. To establish a time-course relating the systemic changes to brain apoptosis we collected a set of
animals exposed to 1.5% isoflurane for 0, 1, 2, 3, or 4 hours. Using this tissue set we observed that cleaved caspase-3 levels increase as a function of exposure time but, critically, induction of apoptosis was not evident until the 4-hour time-point, where cleaved caspase-3 levels in whole brain were ~50% higher than at baseline (Fig 3B).

We also assessed the number of apoptotic cells by probing for cleaved caspase-3 using immunofluorescent staining and confocal imaging, focusing on the hippocampus (Fig 3C–3F, see Methods). As stated above, commercial antibodies required careful selection and extensive optimization (see Discussion) to rigorously detect only cleaved caspase. Apoptosis induction was statistically significant in mice anesthetized for 4 hours in hippocampus, cortex, and cerebellum. Modest induction was observed at 2 hours in cerebellum. Induction was non-significant before 2-hours in every region.

**Impact of extended or repeated anesthesia exposure on learning and memory in P7 neonatal mice**

Given our metabolic findings and apoptosis data we sought to determine if a 2-hour exposure to 1.5% isoflurane leads to cognitive defects. The metabolic state at 2 hours, although grossly abnormal, was less severe than the 4-hour exposure. To test this, we used the Barnes maze paradigm for learning and memory to test young adult (P60) animals that had been exposed to isoflurane or control conditions at P7 (see Methods for details) (Fig 4A–4C). To maximize the utility of this assay we added a final trial, 3 weeks after the closest previous trial on week 3, to assess longer-term memory. We found that a 2-hour anesthesia exposure had no impact on learning, short term memory, or long-term memory in either female (Fig 4E) or male (Fig 4H) animals.

We sought to test the published long-term (4-hour) and repeated (2 hours daily for 3 days) exposure paradigms. Given our metabolic recovery findings (Fig 2), we chose not to consider a 3-exposure per day paradigm as it is overtly not relevant to clinical exposures. As in the 2-hour treatment, we observed no detectable cognitive effects in either female (Fig 4F) or male (Fig 4I) pups as a result of 2-hour exposures repeated for 3 consecutive days or to a single 4-hour exposure, which was lethal to 50% of animals.

The majority of mouse AIN reports provide little description of their control animals, so we considered the possibility that our 'no isoflurane' treatment (removal from parents for the duration of the exposure time, see Methods) was not representative of studies where a cognitive effect was observed; it is possible that in at least some studies the published 'control' animals were not handled prior to behavioral testing. To address this possibility, we included a 'baseline control' group, where animals did not receive a 'mock' exposure; these animals were not handled, aside from normal care, until behavioral testing at P60. We found no differences in female (Fig 4G) or male (Fig 4I) 'baseline control' mice compared to any of the anesthesia paradigms tested (see statistical analyses in Methods).

**Impact of equipotent sevoflurane**

While the majority of neonatal mouse AIN studies have used isoflurane to induce CNS death and behavioral defects (see Table 1), sevoflurane is a newer volatile anesthetic which is preferred in clinical pediatric practice and is becoming more common in pre-clinical research. To determine whether sevoflurane exposure induces physiological changes similar to those observed in neonates exposed to 1.5% isoflurane we repeated the extended duration exposures using sevoflurane at an equipotent dose, 3.5% (see Fig 5A and 5F). As with isoflurane, extended exposure to sevoflurane resulted in progressive respiratory depression (Fig 5B), hypoglycemia (Fig 5C), and hypoketonemia (Fig 5D). Intriguingly, sevoflurane did not induce
the increased blood lactate seen with isoflurane treatment, although we cannot rule out the possibility that there was a transient increase in lactate at some time between the measured points (Fig 5E).

**Anesthetic dose**

To determine whether it is possible to avoid the metabolic effects of anesthesia by reducing the concentration of volatile gas we next tested a lower dose of isoflurane, 1%. Importantly, 1.5% isoflurane and 3.5% sevoflurane are approximately EC95 for loss of righting reflex (LORR) in P7 neonatal mice (Fig 5A and 5F), while 1% isoflurane is well below the EC50 for P7 neonatal animals. Extended 1% isoflurane exposure resulted in a slight respiratory depression by 4 hours (Fig 5G) with hypoglycemia (Fig 5H), a transient reduction in circulating β-hydroxybutyrate (Fig 5I), and an increase in blood lactate by 4 hours of exposure (Fig 5J). While the metabolic changes at 1% isoflurane were less severe than those resulting from exposure to 1.5% isoflurane, these data indicate that extended exposure to volatile anesthetic agents, even at sub-anesthetic doses, results in significant physiological disturbances in P7 neonatal mice.

https://doi.org/10.1371/journal.pone.0213543.g005
Age range of sensitivity

Studies in the mouse model have demonstrated that sensitivity to anesthetic induced neurotoxicity is specific to the neonatal period. To determine the age-range of metabolic sensitivity, e.g., the age-range where exposure to volatile anesthetics for 2 or 4 hours results in severe metabolic derangements, we exposed mice at post-natal day 23 (P23), two-days post-weaning, and post-natal day 26, 5 days post-weaning. In room air, weaned mice have higher blood glucose and lower blood β-hydroxybutyrate than neonates (Fig 6A and 6B). When exposed to 1.5% isoflurane P23 animals show progressive respiratory depression (Fig 6C), hypoglycemia (Fig 6D), and transiently increased lactate (Fig 6F), similarly to neonates. β-hydroxybutyrate, which starts low in P23 mice, increases significantly during a 4-hour exposure, presumably resulting from the induction of fasting induced ketogenesis (Fig 6E). P26 mice, in contrast, show respiratory depression but non-significant changes in glucose (which trends downward) and ketones by 4 hours (Fig 6H–6J). Lactate is increased at 2 hours, but remains stable at 4.

Together, these data suggest that the period of metabolic sensitivity to volatile anesthesia ends shortly after weaning, at which point mice are able to maintain metabolite levels, although some aspects of anesthesia, such as respiratory depression and lactate increase by isoflurane, are still present even at this later age.

Discussion

Our studies demonstrate unexpected consequences of isoflurane exposure in neonatal mice. Severe derangements in respiration, blood glucose, ketones, lactate, and pH lead to a 50% mortality rate for P7 mice exposed to 1.5% isoflurane for 4 hours. Given these results, interpretation of many anesthetic neurotoxicity studies in neonatal mice must entertain confounding factors present in each study.

The majority of mouse AIN reports use 2 or more hours of anesthesia in neonatal mice, typically at P7 (neonatal mouse AIN literature summarized in Table 1). Several studies rely on 6 hours to induce neurotoxicity. Here, we show that this results in an extremely abnormal metabolic and physiological state incomparable to human clinical anesthesia. After only 2-hours P7 mouse pups show severe respiratory depression, hypoglycemia and hypoketolemia, increased blood lactate, and are severely acidotic. The extent of these metabolic defects has not been appreciated previously. By 4-hours, P7 mice are in a state of extreme metabolic and respiratory distress. Mortality reaches ~50% after a single 4-hour exposure, with animals dying during recovery from the anesthetic exposure, a clear indication that this paradigm does not model pediatric clinical anesthesia.

These data provide the most detailed assessment of the physiological impact of anesthesia in neonatal mice to date, but is supported by some published work. Loepke et al [18] assessed some metabolic parameters in neonatal mice exposed 1.5% isoflurane, reporting changes consistent with what we report here. They described hypoglycemia, acidosis, increased lactate, and an increase in apoptosis similar to what we found, with no cognitive defects detected. Interestingly, they used a hybrid mouse (C57Bl/6 x CD-1) for the reported ‘low’ mortality of 18% under their anesthesia protocol. These data are generally consistent with our findings, while the strain used or the carrier gas difference (30% oxygen versus 100% oxygen) may explain any differences. Although these authors do not state the overall mortality of the C57Bl/6 line in their hands they state it is higher than the 18% found with the hybrid line. Given that most mouse AIN studies utilize the C57Bl/6 background (Table 1) we think that our data best mimics the methods of the majority of the mouse AIN literature. It is interesting that many of the studies in Table 1 did not reported high levels of mortality, and this fact is difficult to completely reconcile with our observations. Subtle strain or colony specific effects may partly
Relevance of AIN in mice

Fig 6. Physiological impact of anesthesia as a function of age. (A) Baseline blood glucose in mice at 7 (neonatal), 23 (2 days post-weaning), and 26 days of age. (B) Baseline blood β-hydroxybutyrate in mice at 7 (neonatal), 23 (2 days post-weaning), and 26 days of age. (C) Respiratory rate of P23 mice as a function of time exposed to 1.5% isoflurane. ANOVA p-value < 0.0001; * * * p < 0.0001; ** p < 0.005 post-hoc pairwise t-test. n = 4, 4, and 4 for 0.5, 2, and 4 hours, respectively. (D) P23 mouse blood glucose concentration at baseline and at 2 or 4 hours of anesthesia with 1.5% isoflurane. ANOVA p-value = 0.0009; ** p < 0.0001 post-hoc pairwise t-test. n = 8, 4, and 5 for 0, 2, and 4 hours, respectively. (E) P23 mouse blood β-hydroxybutyrate concentration at baseline and at 2 or 4 hours of anesthesia with 1.5% isoflurane. ANOVA p-value < 0.0004; ** p < 0.0001 post-hoc pairwise t-test. n = 8, 4, and 5 for 0, 2, and 4 hours of exposure, respectively. (F) P26 mouse blood lactate concentration at baseline and at 2 or 4 hours of anesthesia with 1.5% isoflurane. ANOVA p-value = 0.0002; * * * p < 0.001, post-hoc pairwise t-test. n = 8, 4, and 5 for 0, 2, and 4 hours, respectively. (G) Respiratory rate of P26 mice as a function of time exposed to 1.5% isoflurane. ANOVA p-value < 0.0001; * p = 0.001. ** p = 0.0001 post-hoc pairwise t-test. n = 4, 4, and 4 for 0.5, 2, and 4 hours, respectively. (H) P26 mouse blood glucose concentration at baseline and at 2 or 4 hours of anesthesia with 1.5% isoflurane. ANOVA and post-hoc t-tests non-significant (n.s.). n = 4, 4, and 4 for 0, 2, and 4 hours, respectively. (I) P26 mouse blood β-hydroxybutyrate concentration at baseline and at 2 or 4 hours of anesthesia with 1.5% isoflurane. ANOVA and post-hoc t-tests non-significant (n.s.). n = 4, 4, and 4 for 0, 2, and 4 hours, respectively. (J) P26 mouse blood β-hydroxybutyrate concentration at baseline and at 2 or 4 hours of anesthesia with 1.5% isoflurane. ANOVA ** p = 0.006. * p < 0.02 by post-hoc t-tests non-significant. n = 4, 4, and 4 for 0, 2, and 4 hours, respectively.

https://doi.org/10.1371/journal.pone.0213543.g006
account for some variation, while differences in gas composition, or temperature control may also contribute. A comprehensive assessment of the impact of these and other potential confounding factors in neonatal rodent mortality under anesthesia may be valuable.

While we focus in this study on the neonatal mouse model of AIN, our findings are consistent with reports by Stratmann et al [19] and Wu et al [20] who found that long term exposure of neonatal rats to isoflurane or sevoflurane resulted in respiratory depression, hypercarbia, and acidosis. Importantly, these studies provided evidence that in rats the CNS cell death results from these physiological perturbations rather than the anesthesia itself. These reports also suggested that the cognitive effects of anesthetic exposure in young rats are at least partially separable from CNS cell death.

Loepke et al demonstrated that dextrose supplementation does not prevent CNS apoptosis in the hybrid mouse strain exposed to 1.5% isoflurane for 6 hours [18,21]. Here, we show here that in addition to hypoglycemia and acidosis, lactate is increased, respiratory rate is severely depressed, and circulating β-HB is depleted in a much shorter exposure, only 1 hour of anesthesia. Any of these changes may contribute to CNS cell death independent of glucose, but the significant depletion of β-HB is particularly intriguing. Neonatal mice are known to be ketotic compared to adults, and β-HB has been shown to directly regulate histone modifier enzymes, impacting cell differentiation and survival [22–25]. Moreover, β-HB has repeatedly been shown to prevent hypoglycemia induced neuronal damage and dysfunction in neonatal, but not adult, rodent brain slices [23,26–28]. Depletion of β-HB has not been previously reported in the context of AIN, and loss of β-HB may contribute to the increase in apoptosis that we see with isoflurane exposure, or to other neurodevelopmental defects associated with AIN in mice.

In these studies, we found that induction of neuronal apoptosis occurs only after the onset of severe systemic metabolic derangements. Moreover, despite the multiple pathologic effects of isoflurane exposure, we did not detect the extreme increase in apoptosis and CNS degeneration reported by some groups, although the degree of apoptosis induction we observed does agrees with a significant portion of the rodent AIN literature (see references in Table 1). In considering the variable degrees of apoptosis induction reported in the literature, we identified caspase-3 detection as a major potential source of error in studying apoptosis that are often not accounted for in published AIN reports and may contribute to lab to lab variation. We found that cleaved caspase-3 is present at extremely low levels in normal brain, and cleaved caspase-3 detection by Western blot is extremely difficult; half of the commercially available antibodies we tested detected only off-target bands (see Methods). Similarly, immunostaining for cleaved caspase-3 is highly sensitive to autofluorescence and off-target binding. Antibodies which recognize both the cleaved and full-length forms of caspase-3 should never be used, and the high autofluorescence of fixed brain tissue, including strong neuron body fluorescence, must accounted for. Extensive optimization led us to the conclusion that cleaved caspase-3 could not be reliably detected above background using green fluorophores so we opted for the far-red channel.

We detected no overt learning or memory deficits in mice treated with 2- or 4-hours of isoflurane, nor in animals exposed for 2-hours daily for three days. As in the case of cleaved caspase-3 induction, the published literature varies widely, many other laboratories have reported similar findings (for example [29–32]; a 2017 review by Loepke et al found that over a third of animal studies of AIN report either no structure or no cognitive defects [1]). Thus, the lack of overt cognitive effects in our animals indicates that our exposures paradigms were successful in modeling the published neonatal mouse AIN literature. Specifically, we found that the physiological disruptions we observed did not result in behavioral abnormalities more severe than others have reported. In considering those reports which have shown behavioral changes by Barnes maze, we did find that litter to litter variation was high in this assay, indicating that a
lack of sufficient animal numbers or use of few litters could result in false positives due to litter effects. Many of the reports in Table 1 lack a detailed description of anesthesia conditions, and poorly controlled exposures may result in more severe CNS cell death and/or cognitive defects. It is also possible that the mice which perished may have shown the most severe behavioral abnormalities, and that our data thus reflects a ‘survivor effect’ resulting from the loss of these animals. In this scenario, mouse strains with improved survival to 4 hours of exposure would be expected to show more overt cognitive defects, possibly accounting for some of the variance in the literature.

It is likely that isoflurane results in more subtle behavioral abnormalities than we could detect given that the Barnes maze is a relatively insensitive assay. Subtler behavioral effects are likely present following extended exposures to anesthesia but would require more sensitive or specialized assays, as others have reported (reviewed in [1]). We did not attempt to reproduce these published findings as the presence or absence of cognitive defects does not impact our primary findings.

In the clinical setting, monitoring standards for pediatric patients during anesthesia include continual monitoring of oxygenation, ventilation, circulation, and temperature both pre- and post-anesthetic exposure. Preterm neonates also usually receive intraoperative glucose to mitigate risk of hypoglycemic from low glycogen stores and immature gluconeogenesis pathways [33]. Our approach here recapitulates the ‘best controlled’ neonatal mouse AIN literature, including temperature control, 100% oxygen, humidification, and an isoflurane concentration sufficient to anesthetize but not supramaximal. Reports finding more severe apoptosis, neurodegeneration, and/or behavioral effects may partly result from less well-controlled paradigms.

Our data indicate that neonatal mouse AIN paradigms result in severe metabolic and physiological disturbances which precede CNS cell death and, accordingly, neonatal mouse AIN paradigms poorly model human clinical exposures. The work of Stratmann and of Wu [19,20] suggest this may be true for the rat model as well. However, certain aspects of AIN, such as increased CNS apoptosis and cognitive abnormalities, have been reported in larger model species where better physiological control is possible, such as Rhesus monkeys [34–36]. Accordingly, some detrimental effects of anesthesia exposure may be independent of the physiological changes and it may be possible to mechanistically separate these sequelae of anesthesia from the physiological effects in neonatal mice as well. The mouse model will remain useful in assessing the impact of anesthesia exposure if the confounding effects of physiological disruption can be avoided. Conversely, while our findings are specific to the mouse, they show that evaluation of physiological status and clinical relevance is prudent in any animal model. Given our data in mice, a careful assessment of other AIN models may be warranted.

In sum, our findings warrant a careful re-evaluation of the mouse AIN literature and the clinical relevance of mouse AIN findings.

Supporting information

S1 Checklist. Human endpoints checklist. (DOCX)

S1 File. Supporting data. Contains all data presented in this manuscript. Data is organized by figure number, with each figure provided in an individual tab within the spreadsheet file. (XLSX)

Acknowledgments

This work was funded by the NIH through an R01, 5R01GM118514-02, awarded to Dr. Philip Morgan and an NIH grant 1K99GM126147-01 to Dr. Simon Johnson. Rebecca Bornstein was
supported by NIH T32 1T32GM095421-08. Funding was also provided by the Northwest Mitochondrial Research Guild. We thank Dr. Beatrice Predoi, MD, Seattle Children’s Research Institute, Center for Integrative Brain Research, for general technical assistance.

Author Contributions

Conceptualization: Simon C. Johnson, Margaret M. Sedensky, Philip G. Morgan.

Data curation: Simon C. Johnson, Arielle Freed.

Formal analysis: Simon C. Johnson, Arielle Freed.

Funding acquisition: Simon C. Johnson, Margaret M. Sedensky, Philip G. Morgan.

Investigation: Simon C. Johnson, Amanda Pan, Grace X. Sun, Arielle Freed, Julia C. Stokes, Rebecca Bornstein, Michael Witkowski, Li Li, Philip G. Morgan.

Methodology: Simon C. Johnson, Amanda Pan, Grace X. Sun, Arielle Freed, Philip G. Morgan.

Project administration: Simon C. Johnson, Margaret M. Sedensky, Philip G. Morgan.

Resources: Jeremy M. Ford, Christopher R. A. Howard.

Supervision: Simon C. Johnson, Margaret M. Sedensky, Philip G. Morgan.

Validation: Simon C. Johnson.

Visualization: Simon C. Johnson, Philip G. Morgan.

Writing – original draft: Simon C. Johnson.

Writing – review & editing: Simon C. Johnson, Margaret M. Sedensky, Philip G. Morgan.

References

1. Lin EP, Lee JR, Lee CS, Deng M, Loepke AW: Do anesthetics harm the developing human brain? An integrative analysis of animal and human studies. Neurotoxicol Teratol 2017; 60: 117–128 https://doi.org/10.1016/j.ntt.2016.10.008 PMID: 27793659

2. Walters JL, Paule MG: Review of preclinical studies on pediatric general anesthesia-induced developmental neurotoxicity. Neurotoxicol Teratol 2017; 60: 2–23 https://doi.org/10.1016/j.ntt.2016.11.005 PMID: 27871903

3. Vutskits L, Davidson A: Update on developmental anesthetic neurotoxicity. Curr Opin Anaesthesiol 2017; 30: 337–342 https://doi.org/10.1097/ACO.0000000000000461 PMID: 28277380

4. Mann GE, Kahana M: The uncomfortable reality . . . We simply do not know if general anesthesia negatively impacts the neurocognitive development of our small children. Int J Pediatr Otorhinolaryngol 2015; 79: 1379–81 https://doi.org/10.1016/j.ijporl.2015.05.011 PMID: 26143125

5. Davidson AJ, Sun LS: Clinical Evidence for Any Effect of Anesthesia on the Developing Brain. Anesthesiology 2018; 128: 840–853 https://doi.org/10.1097/ALN.0000000000003192 PMID: 29210706

6. Chinn GA, Sasaki Russell JM, Sali JW: Is a short anesthetic exposure in children safe? Time will tell: a focused commentary of the GAS and PANDA trials. Annu Transl Med 2016; 4: 408 https://doi.org/10.21037/atm.2016.10.43 PMID: 27867960

7. Orser BA, Suess S, Evers AS: SmartTots Update Regarding Anesthetic Neurotoxicity in the Developing Brain. Anesth Analg 2018; 126: 1393–1396 https://doi.org/10.1213/ANE.0000000000002833 PMID: 29401076

8. Ing C, DiMaggio C, Whitehouse A, Hegarty MK, Brady J, von Ungern-Sternberg BS, et al.: Long-term differences in language and cognitive function after childhood exposure to anesthesia. Pediatrics 2012; 130: e476–85 https://doi.org/10.1542/peds.2011-3822 PMID: 22908104

9. Glatz P, Sandin RH, Pedersen NL, Bonamy AK, Eriksson LI, Granath F: Association of Anesthesia and Surgery During Childhood With Long-term Academic Performance. JAMA Pediatr 2017; 171: e163470 https://doi.org/10.1001/jamapediatrics.2016.3470 PMID: 27820621
10. Sun LS, Li G, Miller TL, Salorio C, Byrne MW, Bellinger DC, et al.: Association Between a Single General Anesthesia Exposure Before Age 36 Months and Neurocognitive Outcomes in Later Childhood. JAMA 2016; 315: 2312–20 https://doi.org/10.1001/jama.2016.6967 PMID: 27272582

11. Davidson AJ, Disma N, de Graaff JC, Withington DE, Dorris L, Bell G, et al.: GAS: Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS): an international multicentre, randomised controlled trial. Lancet 2016; 387: 239–50 https://doi.org/10.1016/S0140-6736(15)00608-X PMID: 26507180

12. Wang X, Xu Z, Miao CH: Current clinical evidence on the effect of general anesthesia on neurodevelopment in children: an updated systematic review with meta-regression. PLoS One 2014; 9: e85760 https://doi.org/10.1371/journal.pone.0085760 PMID: 2445688

13. Zhang H, Du L, Du Z, Jiang H, Han D, Li Q: Association between childhood exposure to single general anesthesia and neurodevelopment: a systematic review and meta-analysis of cohort study. J Anesth 2015; 29: 749–57 https://doi.org/10.1016/s0054-0015-2030-3 PMID: 26002228

14. hershey JD, Gifford LJ, Zizza LJ, Pavlenko DA, Wagner GC, Miller S: Effects of Various Cleaning Agents on the Performance of Mice in Behavioral Assays of Anxiety. J Am Assoc Lab Anim Sci 2018; 57: 335–339 https://doi.org/10.30802/AAALAS-JAALAS-17-000161 PMID: 29950249

15. Kayser EB, Suthammarak W, Morgan PG, Sedensky MM: Isoflurane selectively inhibits distal mitochondrial complex I in Caenorhabditis elegans. Anesth Analg 2011; 112: 1321–9 https://doi.org/10.1213/ANE.0b013e3182121d37 PMID: 21467554

16. Olufs ZPG, Loewen CA, Ganetzky B, Wassarman DA, Pereouansky M: Genetic variability affects absolute and relative potencies and kinetics of the anesthetics isoflurane and sevoflurane in Drosophila melanogaster. Sci Rep 2018; 8: 2348 https://doi.org/10.1038/s41598-018-20720-7 PMID: 29402974

17. Shen X, Liu Y, Xu S, Zhao Q, Guo X, Shen R, et al.: Early life exposure to sevoflurane impairs adulthood spatial memory in the rat. Neurotoxicology 2013; 39: 45–56 https://doi.org/10.1016/j.neuro.2013.08.007 PMID: 23994303

18. Loepke AW, McCann JC, Kurth CD, McAuliffe JJ: The physiologic effects of isoflurane anesthesia in neonatal mice. Anesth Analg 2006; 102: 75–80 https://doi.org/10.1213/01.ANE.0000181102.92729.B8 PMID: 16368807

19. Stratmann G, May LD, Sall JW, Alvi RS, Bell JS, Ormerod BK, et al.: Effect of hypercarbia and isoflurane on brain cell death and neurocognitive dysfunction in 7-day-old rats. Anesthesiology 2009; 110: 849–61 https://doi.org/10.1097/ALN.0b013e31819c7140 PMID: 19293696

20. Wu B, Yu Z, You S, Zheng Y, Liu J, Gao Y, et al.: Physiological disturbance may contribute to neurodegeneration induced by isoflurane or sevoflurane in 14 day old rats. PLoS One 2014; 9: e84622 https://doi.org/10.1371/journal.pone.0084622 PMID: 24400105

21. Loepke AW, Istatphanous GK, McAuliffe JJ 3rd, Miles L, Hughes EA, McCann JC, et al.: The effects of neonatal isoflurane exposure in mice on brain cell viability, adult behavior, learning, and memory. Anesth Analg 2009; 108: 90–104 https://doi.org/10.1213/ane.0b013e31818c2d9 PMID: 19095836

22. Cotter DG, d’Avignon DA, Wentz AE, Weber ML, Crawford PA: Obligate role for ketone body oxidation in neonatal metabolic homeostasis. J Biol Chem 2011; 286: 6902–10 https://doi.org/10.1074/jbc.M110.192369 PMID: 21209089

23. Wada H, Okada Y, Nabetai N, Nakamura H: The effects of lactate and beta-hydroxybutyrate on the energy metabolism and neural activity of hippocampal slices from adult and immature rat. Brain Res Dev Brain Res 1997; 101: 1–7 PMID: 9263574

24. Newman JC, Verdin E: beta-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract 2014; 106: 173–81 https://doi.org/10.1016/j.diabres.2014.08.009 PMID: 25193333

25. Newman JC, Verdin E: Ketone bodies as signaling metabolites. Trends Endocrinol Metab 2014; 25: 42–52 https://doi.org/10.1016/j.tem.2013.09.002 PMID: 24140022

26. Izumi Y, Ishi K, Katsuki H, Benz AM, Zorumski CF: beta-Hydroxybutyrate fuels synaptic function during development. Histological and physiological evidence in rat hippocampal slices. J Clin Invest 1998; 101: 1121–32 https://doi.org/10.1172/JCI1009 PMID: 9486983

27. Izumi Y, Benz AM, Katsuki H, Zorumski CF: Endogenous monocarboxylates sustain hippocampal synaptic function and morphological integrity during energy deprivation. J Neurosci 1997; 17: 9448–57 PMID: 9391000

28. Youssef FF: Ketone bodies attenuate excitotoxic cell injury in the rat hippocampal slice under conditions of reduced glucose availability. Neurol Res 2015; 37: 211–6 https://doi.org/10.1179/1743132814Y.0000000430 PMID: 25082548

29. Yang B, Liang G, Khjoasteh S, Wu Z, Yang W, Joseph D, et al.: Comparison of neurodegeneration and cognitive impairment in neonatal mice exposed to propofol or isoflurane. PLoS One 2014; 9: e99171 https://doi.org/10.1371/journal.pone.0099171 PMID: 24932894
30. Zhou L, Wang Z, Zhou H, Liu T, Lu F, Wang S, et al.: Neonatal exposure to sevoflurane may not cause learning and memory deficits and behavioral abnormality in the childhood of Cynomolgus monkeys. Sci Rep 2015; 5: 11145 https://doi.org/10.1038/srep11145 PMID: 26046459
31. Murphy KL, McGAughy PL, Croxson PL, Baxter MG: Exposure to sevoflurane anesthesia during development does not impair aspects of attention during adulthood in rats. Neurotoxicol Teratol 2017; 60: 87–94 https://doi.org/10.1016/j.ntt.2016.11.010 PMID: 27919700
32. Liang X, Zhang Y, Zhang C, Tang C, Wang Y, Ren J, et al.: Effect of repeated neonatal sevoflurane exposure on the learning, memory and synaptic plasticity at juvenile and adult age. Am J Transl Res 2017; 9: 4974–4983 PMID: 29218095
33. O’Brien F, Walker IA: Fluid homeostasis in the neonate. Paediatr Anaesth 2014; 24: 49–59 https://doi.org/10.1111/pan.12326 PMID: 24299660
34. Zou X, Liu F, Zhang X, Patterson TA, Callicott R, Liu S, et al.: Inhalation anesthetic-induced neuronal damage in the developing rhesus monkey. Neurotoxicol Teratol 2011; 33: 592–7 https://doi.org/10.1016/j.ntt.2011.06.003 PMID: 21708249
35. Liu F, Rainosek SW, Frisch-Daiello JL, Patterson TA, Paule MG, Slikker W Jr., et al.: Potential Adverse Effects of Prolonged Sevoflurane Exposure on Developing Monkey Brain: From Abnormal Lipid Metabolism to Neuronal Damage. Toxicol Sci 2015; 147: 562–72 https://doi.org/10.1093/toxsci/kfv150 PMID: 26206149
36. Alvarado MC, Murphy KL, Baxter MG: Visual recognition memory is impaired in rhesus monkeys repeatedly exposed to sevoflurane in infancy. Br J Anaesth 2017; 119: 517–523 https://doi.org/10.1093/bja/aew473 PMID: 28575197
37. Song Q, Ma YL, Song QJ, Chen Q, Xia GS, Ma JY, et al.: Sevoflurane induces neurotoxicity in young mice through FAS/FASL signaling. Genet Mol Res 2015; 14: 18059–68 https://doi.org/10.4238/2015.December.22.32 PMID: 26782435
38. Sun Z, Satomoto M, Adachi YU, Kinoshita H, Makita K: Inhibiting NADPH oxidase protects against long-term memory impairment induced by neonatal sevoflurane exposure in mice. Br J Anaesth 2016; 117: 80–6 https://doi.org/10.1093/bja/aew064 PMID: 27147542
39. Lee JH, Park YH, Song HG, Park HP, Kim HS, Kim CS, et al.: The effect of lidocaine on apoptotic neurodegeneration in the developing mouse brain. Korean J Anesthesiol 2014; 67: 334–41 https://doi.org/10.4097/kjane.2014.67.5.334 PMID: 25473463
40. Johnson SA, Young C, Olney JW: Isoflurane-induced neuroapoptosis in the developing brain of nonhypoglycemic mice. J Neurosurg Anesthesiol 2008; 20: 21–8 https://doi.org/10.1097/ANA.0b013e3181271850 PMID: 1897021
41. Zhu C, Gao J, Karlsson N, Li Q, Zhang Y, Huang Z, et al.: Isoflurane anesthesia induced persistent, progressive memory impairment, caused a loss of neural stem cells, and reduced neurogenesis in young, but not adult, rodents. J Cereb Blood Flow Metab 2010; 30: 1017–30 https://doi.org/10.1038/jcbfm.2009.274 PMID: 20068576
42. Zhang L, Zhang J, Dong Y, Swain CA, Zhang Y, Xie Z: The potential dual effects of sevoflurane on AKT/GSK3beta signaling pathway. Med Gas Res 2014; 4: 5 https://doi.org/10.1186/2045-9912-4-5 PMID: 24580743
43. Liu J, Yang J, Xu Y, Guo G, Cai L, Wu H, et al.: Roscovitine, a CDK5 Inhibitor, Alleviates Sevoflurane-Induced Cognitive Dysfunction via Regulation Tau/GSK3beta and ERK/PPARgamma/CREB Signaling. Cell Physiol Biochem 2017; 44: 423–435 https://doi.org/10.1159/000485008 PMID: 2914245
44. Tao G, Xue Q, Luo Y, Li G, Xia Y, Yu B: Isoflurane Is More Deleterious to Developing Brain Than Desflurane: The Role of the Akt/GSK3beta Signaling Pathway. Biomed Res Int 2016; 2016: 7919640 https://doi.org/10.1155/2016/7919640 PMID: 27057548
45. Satomoto M, Sun Z, Adachi YU, Makita K: Sugammadex-Enhanced Neuronal Apoptosis following Neonatal Sevoflurane Exposure in Mice. Anesthesiol Res Pract 2016; 2016: 9682703 https://doi.org/10.1155/2016/9682703 PMID: 27895665
46. Ji MH, Qiu LL, Yang JJ, Zhang H, Sun XR, Zhu SH, et al.: Pre-administration of curcumin prevents neonatal sevoflurane exposure-induced neurobehavioral abnormalities in mice. Neurotoxicology 2015; 46: 155–64 https://doi.org/10.1016/j.neuro.2014.11.003 PMID: 25447320
47. Man YG, Zhou RG, Zhao B: Efficacy of rutin in inhibiting neuronal apoptosis and cognitive disturbances in sevoflurane or propofol exposed neonatal mice. Int J Clin Exp Med 2015; 8: 14397–409 PMID: 26550427
48. Tagawa T, Sakuraba S, Kimura K, Mizoguchi A: Sevoflurane in combination with propofol, not thiopental, induces a more robust neuroapoptosis than sevoflurane alone in the neonatal mouse brain. J Anesth 2014; 28: 815–20 https://doi.org/10.1007/s00540-014-1822-x PMID: 24705982
49. Lin XF, Han YQ, Li HL, Zhao YP, Fei XJ, Sheng JX, et al.: SAHA attenuates sevoflurane-induced learning and memory impairments in fetal mice. Genet Mol Res 2014; 13: 10769–78. https://doi.org/10.4238/2014.December.18.18 PMID: 25526197

50. Xu KX, Tao J, Zhang N, Wang JZ: Neuroprotective properties of vitamin C on equipotent anesthetic concentrations of desflurane, isoflurane, or sevoflurane in high fat diet fed neonatal mice. Int J Clin Exp Med 2015; 8: 1044–58 PMID: 26379835

51. Han XD, Li M, Zhang XG, Xue ZG, Cang J: Single sevoflurane exposure increases methyl-CpG island binding protein 2 phosphorylation in the hippocampus of developing mice. Mol Med Rep 2015; 11: 226–30. https://doi.org/10.3892/mmr.2014.2751 PMID: 25338822

52. Xu G, Lu H, Dong Y, Shapoval D, Soriano SG, Liu X, et al.: Coenzyme Q10 reduces sevoflurane-induced cognitive deficiency in young mice. Br J Anaesth 2017; 119: 481–491. https://doi.org/10.1093/bja/aex071 PMID: 28482003

53. Cheng Y, He L, Prasad V, Wang S, Levy RJ: Anesthesia-Induced Neuronal Apoptosis in the Developing Retina: A Window of Opportunity. Anesth Analg 2015; 121: 1325–35. https://doi.org/10.1213/ANE.0000000000002751 PMID: 26465931

54. Cheng Y, Levy RJ: Subclinical carbon monoxide limits apoptosis in the developing brain after isoflurane exposure. Anesth Analg 2014; 118: 1284–92. https://doi.org/10.1213/ANE.0000000000002441 PMID: 24413549

55. Chung W, Park S, Hong J, Park S, Lee S, Heo J, et al.: Sevoflurane exposure during the neonatal period induces long-term memory impairment but not autism-like behaviors. Paediatr Anaesth 2015; 25: 1033–45. https://doi.org/10.1111/pan.12694 PMID: 26095314

56. Liu J, Zhao Y, Yang J, Zhang X, Zhang W, Wang P: Neonatal Repeated Exposure to Isoflurane not Sevoflurane in Mice Reversibly Impaired Spatial Cognition at Juvenile-Age. Neurochem Res 2017; 42: 595–605. https://doi.org/10.1007/s11064-016-2114-7 PMID: 27882447

57. Istaphanous GK, Howard J, Nan X, Hughes EA, McCann JC, McAuliffe JJ, et al.: Comparison of the neuroapoptotic properties of equipotent anesthetic concentrations of desflurane, isoflurane, or sevoflurane in neonatal mice. Anaesthesia 2011; 114: 578–87. https://doi.org/10.1097/ALN.0b013e3182084a70 PMID: 21293251

58. Hofacer RD, Deng M, Ward CG, Joseph B, Hughes EA, Jiang C, et al.: Cell age-specific vulnerability of neurons to anesthetic toxicity. Ann Neurol 2013; 73: 695–704. https://doi.org/10.1002/ana.23892 PMID: 23526697

59. Liang G, Ward C, Peng J, Zhao Y, Huang B, Wei H: Isoflurane causes greater neurodegeneration than an equivalent exposure of sevoflurane in the developing brain of neonatal mice. Anesthesiology 2010; 112: 1325–34. https://doi.org/10.1097/ALN.0b013e3181d94da5 PMID: 20460994